FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma.

ABSTRACT:

Background

Neoadjuvant immunotherapy has become the new standard of care for stage III melanoma. This study sought to describe the metabolic changes seen with fludeoxyglucose-18-positron emission tomography (FDG-PET) following neoadjuvant immunotherapy in patients with melanoma and explore associations with pathological response and recurrence-free survival (RFS).

Methods

Data from patients with macroscopic stage III nodal melanoma treated with neoadjuvant checkpoint inhibitor therapy were pooled from five melanoma centers. All patients underwent baseline and preoperative FDG-PET and CT assessments, and all had surgery. Pathological response was determined using the International Neoadjuvant Melanoma Consortium criteria, radiological response using Response Evaluation Criter

SUBMITTER: Zhou L 

PROVIDER: S-EPMC11938238 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature